Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$146.01 USD
-0.83 (-0.57%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $143.59 -2.42 (-1.66%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$146.01 USD
-0.83 (-0.57%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $143.59 -2.42 (-1.66%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum B VGM
Zacks News
Will Quest Diagnostics (DGX) Pull a Surprise in Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics Inc. (DGX) is scheduled to report first-quarter 2017 earnings results before the opening bell on Apr 20.
Quest Diagnostics Partners with Veracyte for Cancer Testing
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) has recently entered into an agreement with genomic diagnostics company Veracyte, Inc. (VCYT), for the extended access of Afirma Gene Expression Classifier (GEC).
Quest Diagnostics (DGX): Tops Q4 Earnings, Sales in Line
by Zacks Equity Research
Quest Diagnostics (DGX) earnings per share has beaten Zacks Consensus Estimate while sales were in line with the mark.
Should You Buy Quest Diagnostics (DGX) Ahead of Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
IBM Corp (IBM) Beats on Q4 Earnings; FY17 View Positive
by Zacks Equity Research
International Business Machines Corp (IBM) reported fourth-quarter 2016 non-GAAP earnings of $5.01 per share, which increased 3.5% from the year-ago quarter.
Quest Diagnostics (DGX) Launches HBV Quantitative Test
by Zacks Equity Research
Quest Diagnostics Inc. (DGX), a global provider of diagnostic information services, recently rolled out Hepatitis B Virus (HBV) Quantitative Test.
Quest Diagnostics (DGX) Q4 Earnings: What Lies in Store?
by Zacks Equity Research
Quest Diagnostics Inc. (DGX) is scheduled to report fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 26, 2017.
Anthem Extends Alliance with Inovalon, Boosts Customer Value
by Zacks Equity Research
Leading U.S.-based Health Maintenance Organization (HMO), Anthem Inc. (ANTM), recently declared a multi-year extension of its partnership with Inovalon Holdings, Inc. (INOV).
Quest Diagnostics: Strong Q3, Strategic Initiatives Add Value
by Zacks Equity Research
On Dec 27, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
New Research Reports on NFLX, AXP, GM & Others
by Sheraz Mian
Today's must-read reports are for Netflix (NFLX), American Express (AXP) and General Motors (GM).